Torben Fog – A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Torben Fog – A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research. / Sørensen, Per Soelberg; Bramow, Stephan; Magyari, Melinda; Werdelin, Lene; Koch-Henriksen, Nils; Vermersch, Patrick; Sellebjerg, Finn.

I: Multiple Sclerosis Journal, 2024.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Sørensen, PS, Bramow, S, Magyari, M, Werdelin, L, Koch-Henriksen, N, Vermersch, P & Sellebjerg, F 2024, 'Torben Fog – A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research', Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241239506

APA

Sørensen, P. S., Bramow, S., Magyari, M., Werdelin, L., Koch-Henriksen, N., Vermersch, P., & Sellebjerg, F. (Accepteret/In press). Torben Fog – A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241239506

Vancouver

Sørensen PS, Bramow S, Magyari M, Werdelin L, Koch-Henriksen N, Vermersch P o.a. Torben Fog – A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research. Multiple Sclerosis Journal. 2024. https://doi.org/10.1177/13524585241239506

Author

Sørensen, Per Soelberg ; Bramow, Stephan ; Magyari, Melinda ; Werdelin, Lene ; Koch-Henriksen, Nils ; Vermersch, Patrick ; Sellebjerg, Finn. / Torben Fog – A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research. I: Multiple Sclerosis Journal. 2024.

Bibtex

@article{7e37495686b741599c49b530d250ddb3,
title = "Torben Fog – A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research",
abstract = "Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987. His research was multi-facetted, making him one of the great pioneers in the study of essential parts of the pathology, immunology and treatment of MS. He has contributed with meticulous studies of the MS plaques, documenting the perivenous distribution of plaques in the spinal cord. He constructed a scoring system for the disability in MS and used a computer programme to calculate a total neurological deficit. Together with his co-workers, Fog in 1972 was the first to report the association between MS and the human leukocyte antigen system. Fog can be considered as the father of immunomodulatory therapy in MS, treating MS patients with the first transfer factor, and as early as 1980, he was the first to treat MS with intramuscular natural interferon.",
keywords = "clinical trial, disease modifying therapies, Multiple sclerosis, multiple sclerosis pathology",
author = "S{\o}rensen, {Per Soelberg} and Stephan Bramow and Melinda Magyari and Lene Werdelin and Nils Koch-Henriksen and Patrick Vermersch and Finn Sellebjerg",
note = "Publisher Copyright: {\textcopyright} The Author(s), 2024.",
year = "2024",
doi = "10.1177/13524585241239506",
language = "English",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",

}

RIS

TY - JOUR

T1 - Torben Fog – A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research

AU - Sørensen, Per Soelberg

AU - Bramow, Stephan

AU - Magyari, Melinda

AU - Werdelin, Lene

AU - Koch-Henriksen, Nils

AU - Vermersch, Patrick

AU - Sellebjerg, Finn

N1 - Publisher Copyright: © The Author(s), 2024.

PY - 2024

Y1 - 2024

N2 - Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987. His research was multi-facetted, making him one of the great pioneers in the study of essential parts of the pathology, immunology and treatment of MS. He has contributed with meticulous studies of the MS plaques, documenting the perivenous distribution of plaques in the spinal cord. He constructed a scoring system for the disability in MS and used a computer programme to calculate a total neurological deficit. Together with his co-workers, Fog in 1972 was the first to report the association between MS and the human leukocyte antigen system. Fog can be considered as the father of immunomodulatory therapy in MS, treating MS patients with the first transfer factor, and as early as 1980, he was the first to treat MS with intramuscular natural interferon.

AB - Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987. His research was multi-facetted, making him one of the great pioneers in the study of essential parts of the pathology, immunology and treatment of MS. He has contributed with meticulous studies of the MS plaques, documenting the perivenous distribution of plaques in the spinal cord. He constructed a scoring system for the disability in MS and used a computer programme to calculate a total neurological deficit. Together with his co-workers, Fog in 1972 was the first to report the association between MS and the human leukocyte antigen system. Fog can be considered as the father of immunomodulatory therapy in MS, treating MS patients with the first transfer factor, and as early as 1980, he was the first to treat MS with intramuscular natural interferon.

KW - clinical trial

KW - disease modifying therapies

KW - Multiple sclerosis

KW - multiple sclerosis pathology

U2 - 10.1177/13524585241239506

DO - 10.1177/13524585241239506

M3 - Journal article

C2 - 38523325

AN - SCOPUS:85189134204

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

ER -

ID: 388016337